What is HC Wainwright’s Forecast for ATXS Q1 Earnings?

Astria Therapeutics, Inc. (NASDAQ:ATXS) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Astria Therapeutics in a research note issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.50) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01.

A number of other research firms also recently issued reports on ATXS. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Wedbush reissued an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $26.67.

Astria Therapeutics Stock Performance

ATXS opened at $6.45 on Friday. The firm has a 50 day moving average price of $7.19 and a 200 day moving average price of $9.57. The company has a market cap of $364.00 million, a PE ratio of -3.09 and a beta of 0.69. Astria Therapeutics has a 1 year low of $5.73 and a 1 year high of $16.90.

Institutional Trading of Astria Therapeutics

Several large investors have recently bought and sold shares of the company. FMR LLC grew its position in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. grew its position in Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares in the last quarter. Vestal Point Capital LP grew its position in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $25,680,000. Finally, Vanguard Group Inc. grew its position in Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after acquiring an additional 41,833 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.